Purinergic Signaling of ATP in COVID-19 Associated Guillain-Barré Syndrome

Simões, Júlia Leão Batista; Bagatini, Margarete Dulce

doi:10.1007/s11481-020-09980-1

Cited by 20 publications

(12 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…iScience 24, 103478, December 17, 2021 iScience Article ATP and its metabolites have become a critical component of multiple diseases, including HIV and COVID-19 (Abouelkhair, 2020;Alves et al, 2020;de Oliveira et al, 2021;Dos Anjos et al, 2020;Edwards, 2021;Fonteles et al, 2020;Franciosi et al, 2021;Klaver and Thurnher, 2021;Mishra et al, 2021;Pacheco and Faria, 2021;Shan et al, 2020;Simoes and Bagatini, 2021). Our data in long-term HIV-infected individuals indicate that several chronic effects of HIV are correlated with ATP dysfunction and vascular disease, such as cognitive impairment (Velasquez et al, 2020).…”

Section: Ll Open Accessmentioning

confidence: 72%

Pannexin-1 channel opening is critical for COVID-19 pathogenesis

Luu¹,

Valdebenito²,

Scemes³

et al. 2021

iScience

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly rampaged worldwide, causing a pandemic of coronavirus disease (COVID -19), but the biology of SARS-CoV-2 remains under investigation. We demonstrate that both SARS-CoV-2 spike protein and human coronavirus 229E (hCoV-229E) or its purified S protein, one of the main viruses responsible for the common cold, induce the transient opening of Pannexin-1 (Panx-1) channels in human lung epithelial cells. However, the Panx-1 channel opening induced by SARS-CoV-2 is greater and more prolonged than hCoV-229E/S protein, resulting in an enhanced ATP, PGE 2 , and IL-1b release. Analysis of lung lavages and tissues indicate that Panx-1 mRNA expression is associated with increased ATP, PGE 2 , and IL-1b levels. Panx-1 channel opening induced by SARS-CoV-2 spike protein is angiotensin-converting enzyme 2 (ACE-2), endocytosis, and furin dependent. Overall, we demonstrated that Panx-1 channel is a critical contributor to SARS-CoV-2 infection and should be considered as an alternative therapy.

show abstract

Section: Ll Open Accessmentioning

confidence: 72%

Pannexin-1 channel opening is critical for COVID-19 pathogenesis

Luu¹,

Valdebenito²,

Scemes³

et al. 2021

iScience

View full text Add to dashboard Cite

show abstract

“…CD8 + T cells and NKT cells lacking CD73 exhibit increased cytotoxic effector capacity compared to their counterpart CD73 + [ 164 ]. P2X7R hyperactivation has been reported in COVID-19 as a key driver of inflammation and NLRP3 inflammasome activation [ 165 , 166 ], potentially driving central nervous system diseases [ 165 , 167 ]…”

Section: Viral Infectionsmentioning

confidence: 99%

Purinergic modulation of the immune response to infections

Eberhardt

Bergero

Mariotta

et al. 2022

Purinergic Signalling

View full text Add to dashboard Cite

Infectious diseases are caused by the invasion of pathogenic microorganisms such as fungi, bacteria, viruses, and parasites. After infection, disease progression relies on the complex interplay between the host immune response and the microorganism evasion strategies. The host’s survival depends on its ability to mount an efficient protective anti-microbial response to accomplish pathogen clearance while simultaneously preventing tissue injury by keeping under control the excessive inflammatory process. The purinergic system has the dual function of regulating the immune response and triggering effector antimicrobial mechanisms. This review provides an overview of the current knowledge of the modulation of innate and adaptive immunity driven by the purinergic system during parasitic, bacterial and viral infections.

show abstract

“…Thus, it is understood that the permanence or initiation of therapy, in general, is safe, although theoretical questions raise doubts. Experts claim that this drug can reduce the movement of lymphocytes in the lungs and mucosa, potentiating viral elimination [112]; similarly, with reduced immune surveillance in the CNS, there is concern about a neuronal invasion [113] and the potential development of SARS-CoV-2 encephalitis. To date, two cases of MS patients following therapy and infected have been reported, both have had mild strokes and complete recovery, with no neurological symptoms or suspected encephalitis.…”

Section: Natalizumabmentioning

confidence: 99%

Anti-inflammatory Therapy by Cholinergic and Purinergic Modulation in Multiple Sclerosis Associated with SARS-CoV-2 Infection

2021

Self Cite

View full text Add to dashboard Cite

The virus "acute respiratory syndrome coronavirus 2" (SARS-CoV-2) is the etiologic agent of coronavirus disease 2019 , initially responsible for an outbreak of pneumonia in Wuhan, China, which, due to the high level of contagion and dissemination, has become a pandemic. The clinical picture varies from mild to critical cases; however, all of these signs already show neurological problems, from sensory loss to neurological diseases. Thus, patients with multiple sclerosis (MS) infected with the new coronavirus are more likely to develop severe conditions; in addition to worsening the disease, this is due to the high level of pro-inflammatory cytokines, which is closely associated with increased mortality both in COVID-19 and MS. This increase is uncontrolled and exaggerated, characterizing the cytokine storm, so a possible therapy for this neuronal inflammation is the modulation of the cholinergic anti-inflammatory pathway, since acetylcholine (ACh) acts to reduce pro-inflammatory cytokines and acts directly on the brain for being released by cholinergic neurons, as well as acting on other cells such as immune and blood cells. In addition, due to tissue damage, there is an exacerbated release of adenosine triphosphate (ATP), potentiating the inflammatory process and activating purinergic receptors which act directly on neuroinflammation and positively modulate the inflammatory cycle. Associated with this, in neurological pathologies, there is greater expression of P2X7 in the cells of the microglia, which positively activates the immune inflammatory response. Thus, the administration of blockers of this receptor can act in conjunction with the action of ACh in the anticholinergic inflammatory pathway. Finally, there will be a reduction in the cytokine storm and triggered hyperinflammation, as well as the level of mortality in patients with multiple sclerosis infected with SARS-CoV-2 and the development of possible neurological damage.

show abstract

Purinergic Signaling of ATP in COVID-19 Associated Guillain-Barré Syndrome

Cited by 20 publications

References 85 publications

Pannexin-1 channel opening is critical for COVID-19 pathogenesis

Pannexin-1 channel opening is critical for COVID-19 pathogenesis

Purinergic modulation of the immune response to infections

Anti-inflammatory Therapy by Cholinergic and Purinergic Modulation in Multiple Sclerosis Associated with SARS-CoV-2 Infection

Contact Info

Product

Resources

About